Arcturus Therapeutics (ARCT) Reiterated at Overweight by Cantor Fitzgerald

September 24, 2026 7:17 AM

Cantor Fitzgerald analyst Pete Stavropoulos reiterated an Overweight rating on Arcturus Therapeutics (NASDAQ: ARCT).The analyst commented, "ARCT disclosed additional P2 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found